Patients (189) were divided into three groups with consolidation immunotherapy: control arm with durvalumab monotherapy, arm A with durvalumab in combination with oleclumab (human monoclonal antibody targeting the ectonucleotidase CD73), and arm B with durvalumab in combination with monalizumab (immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor cells which prevents inhibition of CD8 + T cells and NK cell). This evidence concerns the gene CD8A and neoplasm.